FROM:

FAX NO. :

Feb. 12 1998 07:29AM P1

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope

addressed to: Commissioner for Patents PO Box 1450, Alexandria, VA 22313-1450, on

MERAH STABLE

November 14, 200 Beyer Weaver & Thomas, LLF

Atty Docket No: 407T-895413US Client Ref: 1992-206-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PAUL A. PRICE and JULIA S. JOHANSEN

Application No.: 10/648,811

Filed: 08/25/2003

For: ASSAY OF YKL-40 AS A MARKER FOR DEGREDATION OF MAMMALIAN CONNECTIVE TISSUE MATRICES

Examiner: Bag thuy L. Nguyen

Art Unit: 1654

Confirmation No: 5266

DECLARATION UNDER 37 C.F.R.

§1.132

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

I Paul A. Price hereby declare:

I, together with J. S. Johansen, M. Hansen, K. Hørslev-Petersen, and I. Lorenzen was author of the Abstract entitled, "Plasma YKL-40 Conc. In Patients With Rheumatoid Arthritis, Changes During Pulse Treatment with Methylprednisolone", Abstract for scientific conference published on or after July 12, 1992, in Davos, Switzerland, which I understand was cited as a 35 U.S.C. §102(a) reference in the above-identified patent application.

Paul A. Price (P.A. Price) and Julia S. Johansen (J.S. Johansen) are the sole inventors of the subject matter which is disclosed in the above-identified article and which is disclosed and claimed in the above-referenced patent application.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine

App. No: 10/648,811

Page 2

or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated October 25, 2006

Paul A. Price

c:\text{c:\text{c:\text{toms} work}_prosecution - current\text{407t} uc ott\text{407t-911230us oral peptido\text{407t-911230us katz.dec.doc}}